Welcome to our dedicated page for CytoMed Therapeutics SEC filings (Ticker: GDTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CytoMed Therapeutics Limited filings document foreign private issuer disclosures for a clinical-stage cell therapy company. Form 6-K reports furnish clinical and regulatory updates for CAR γδ T cell, iPSC-derived γδ NKT cell, γδ T cell, and cord blood-derived Natural Killer cell programs, along with annual financial results and research expense disclosures.
The filing record also covers annual general meeting materials, proxy voting items, subsidiary structure changes, completed technology and asset acquisitions, non-dilutive subsidiary financing, and shareholder communication matters. These documents frame CytoMed's governance, capital resources, development spending, and corporate organization across Singapore and Malaysia.
CytoMed Therapeutics Limited reported that its Executive Chairman and substantial shareholder, Mr. Choo Chee Kong, increased his shareholding through recent open‑market purchases of 105,824 shares.
According to the accompanying press release title, his effective ownership is now 21.95%. The update was furnished on a Form 6‑K dated October 22, 2025.
CytoMed Therapeutics Limited reported that it has submitted a cash bid of an undisclosed sum for a potential acquisition of selected, potentially synergistic assets of TC BioPharm Limited. The announcement was made on October 14, 2025, and notes that TC BioPharm entered administration on October 2, 2025.
The update signals an interest in expanding CytoMed’s capabilities through asset acquisition, though terms and valuation were not disclosed. A related press release is furnished as Exhibit 99.1. As this is a bid for assets rather than a completed transaction, outcomes and financial effects depend on subsequent developments and any negotiated terms.
CytoMed Therapeutics Limited filed a Form 6-K to share that it issued a press release about new collaborative research with The University of Texas MD Anderson Cancer Center. The publication describes research demonstrating the potential of CytoMed’s allogeneic γδ T cells to treat acute myeloid leukemia, a type of blood cancer. The filing itself mainly serves to make this scientific update available to investors and includes the full press release as an exhibit.
CytoMed Therapeutics Limited furnished a Form 6-K providing its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025, together with management’s discussion and analysis of financial condition and results of operations for the same period.
The company also scheduled a Zoom conference call for the investment community on October 2, 2025 at 10 a.m. ET to discuss these financial results.
CytoMed Therapeutics Ltd (GDTC) filed a Form 144 notifying a proposed sale of 54,644 ordinary shares with an aggregate market value of $102,731 to be sold approximately on 09/23/2025 on NASDAQ. The filer reports total outstanding shares of 11,733,712. The securities were originally acquired by share subscription on 04/22/2021 (payment noted as cash on 04/20/2021) totaling 711,822 shares at acquisition. The filing also lists prior open-market sales by the same account during Aug–Sep 2025 totaling 26,838 shares sold over multiple dates, with individual gross proceeds reported per sale. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
CytoMed Therapeutics Ltd (GDTC) filed a Form 144 notifying a proposed sale of 54,644 ordinary shares with an aggregate market value of $102,731 to be sold approximately on 09/23/2025 on NASDAQ. The filer reports total outstanding shares of 11,733,712. The securities were originally acquired by share subscription on 04/22/2021 (payment noted as cash on 04/20/2021) totaling 711,822 shares at acquisition. The filing also lists prior open-market sales by the same account during Aug–Sep 2025 totaling 26,838 shares sold over multiple dates, with individual gross proceeds reported per sale. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
CytoMed Therapeutics Limited reported that it has successfully expanded clinical-scale natural killer (NK) cells from cord blood units, adding to its existing adult peripheral blood mononuclear cell-derived therapeutics. The company intends to reorganize and streamline its group structure to create a new cord blood-derived biotech business. According to the referenced press release, this move supports an expansion into auto-immune diseases and builds on a recent cord blood bank acquisition.
CytoMed Therapeutics Limited (GDTC) prospectus supplement (Form 424B5) provides table-of-contents items and partial financial and capitalization data related to an offering and pro forma adjustments. The filing shows ordinary shares outstanding of 11,540,000 on an actual basis, 11,836,348 pro forma and 14,268,520 as adjusted (assuming 2,432,172 shares issued in the offering). Total liabilities are presented as 1,023,960 and 749,495 (two comparative figures). Accumulated losses are shown as (14,848,135) and (10,868,200) with pro forma accumulated losses of (16,224,695) and (11,875,783). Total capitalization appears as 10,067,749 and 7,369,162 with an as-adjusted capitalization of 15,587,229 and 11,409,185. Net tangible assets are reported as 8,950,739 and 6,551,558 and as-adjusted 14,470,219 and 10,591,581, with net tangible asset per share figures around $0.78, $0.57, and as-adjusted $1.01/$0.74. The supplement also includes Malaysian tax rate references (examples: 17%, 24%, royalties 10%, interest 15%, dividends exempt). Much of the provided text is a table of contents and fragmented table rows rather than full narrative disclosure.
CytoMed Therapeutics (GDTC) filed a Form 6-K to furnish a 21 Jul 2025 press release. The company has completed Dose Level 1 of its first-in-human Phase I dose-escalation “ANGELICA” trial of CTM-N2D, an investigational cell therapy for patients with advanced solid tumours or haematological malignancies, and has been cleared to begin Dose Level 2. The milestone indicates initial safety/tolerability at the starting dose, a prerequisite for further escalation and eventual efficacy assessment.
The filing contains no financial data, guidance, or corporate transactions; its sole purpose is to publicly disclose this clinical progress (Exhibit 99.1). Investors should view the news as an early-stage, non-pivotal signal of programme momentum rather than a determinant of near-term revenue.